Felipe Rojas-Rodríguez, Bioinformatician at Sanquin, shared a post on LinkedIn:
“Our latest paper is now published in Genome Medicine.
We investigated whether rare germline variants in breast cancer predisposition genes, some involved in DNA damage repair, shape the tumor immune microenvironment, using data from ~8,000 women in the BRIDGES study (Breast Cancer Association Consortium).
Carriers of protein-truncating variants in BRCA1, BRCA2, PALB2, and RAD51D showed higher CD163+ cell abundance, a marker of immunosuppressive, M2-like tumor-associated macrophages. These findings support a role for rare pathogenic germline variants in breast tumors immune composition.
Thank you to Marjanka Schmidt, Renske Keeman, and Sander Canisius at The Netherlands Cancer Institute, and to Paul Pharoah, Mustapha Abubakar and all collaborators within the Breast Cancer Association Consortium.”
Title: The contribution of rare germline variants to the immune landscape of breast cancer
Authors: Felipe Rojas-Rodríguez, Sander Canisius, Renske Keeman, Aaron J. Bernstein, Amber N. Hurson, Thomas U. Ahearn, Irene L. Andrulis, Antonis C. Antoniou, Sabine Behrens, Katarzyna Białkowska, Fiona M. Blows, Manjeet K. Bolla, Nicola J. Camp, Melissa H. Cessna, Jenny Chang-Claude, Stephen J. Chanock, Joe Dennis, Peter Devilee, Alison M. Dunning, Jacek Gronwald, Ute Hamann, Antoinette Hollestelle, Maartje J. Hooning, Hugo M. Horlings, Agnes Jager, Anna Jakubowska, Brandt Jones, Rudolf Kaaks, Marleen Kok, Jolanta Lissowska, Jan Lubiński, Mehdi Manoochehri, Jodi L. Miller, Noor Muhammad, Anna Marie Mulligan, Nadia Obi, Muhammad U. Rashid, Hans-Peter Sinn, Carolien H. M. van Deurzen, Qin Wang, Justin A. Williams, Xiaohong R. Yang, Douglas F. Easton, H. Raza Ali, Montserrat García-Closas, Paul D. P. Pharoah, Mustapha Abubakar, Marjanka K. Schmidt
Read the Full Article.

You can also read:
NeoCarbo Study: Can HRD Identify Triple-Negative Breast Cancers More Likely to Respond to Platinum-Based Neoadjuvant Therapy?
